Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Albireo Pharma, Inc. (NASDAQ:ALBO) Just Reported And Analysts Have Been Cutting Their Estimates
10:25am, Monday, 11'th May 2020
It's been a good week for Albireo Pharma, Inc. (NASDAQ:ALBO) shareholders, because the company has just released its...
Albireo Pharma, Inc. (ALBO) Q1 2020 Earnings Call Transcript
07:30am, Friday, 08'th May 2020
ALBO earnings call for the period ending March 31, 2020.
Recap: Albireo Pharma Q1 Earnings
11:45am, Thursday, 07'th May 2020
Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 60.43% year over year to ($2.23), which may
Albireo Reports Q1 2020 Financial Results and Provides Business Update
11:30am, Thursday, 07'th May 2020
— Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020 —— First sites initiated for second pivotal trial in biliary atresia —— Management to host.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
How Does Albireo Pharma, Inc. (NASDAQ:ALBO) Affect Your Portfolio Volatility?
12:34pm, Sunday, 03'rd May 2020
If you're interested in Albireo Pharma, Inc. (NASDAQ:ALBO), then you might want to consider its beta (a measure of...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Albireo to Report First Quarter 2020 Financial Results on May 7
01:47pm, Thursday, 30'th Apr 2020
BOSTON, April 30, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
Albireo Pharma (NASDAQ:ALBO) Raised to Buy at BidaskClub
10:42am, Saturday, 25'th Apr 2020
Albireo Pharma (NASDAQ:ALBO) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday, BidAskClub reports. Other equities research
Albireo Pharma Inc (NASDAQ:ALBO) Shares Sold by Goldman Sachs Group Inc.
08:52am, Saturday, 25'th Apr 2020
Goldman Sachs Group Inc. reduced its position in shares of Albireo Pharma Inc (NASDAQ:ALBO) by 66.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Sec
Needham Maintains Their Buy Rating on Albireo Pharma (ALBO)
09:11pm, Tuesday, 14'th Apr 2020
In a report released today, Alan Carr from Needham maintained a Buy rating on Albireo Pharma (ALBO – Research Report),
William Blair Sticks to Its Buy Rating for Albireo Pharma (ALBO)
07:37pm, Thursday, 09'th Apr 2020
In a report released yesterday, Tim Lugo from William Blair maintained a Buy rating on Albireo Pharma (ALBO – Research
Man Group plc Sells 98,663 Shares of Albireo Pharma Inc (NASDAQ:ALBO)
12:02pm, Wednesday, 08'th Apr 2020
Man Group plc lowered its stake in Albireo Pharma Inc (NASDAQ:ALBO) by 51.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional inve
Albireo to Present at 19th Annual Needham Healthcare Conference
12:30pm, Tuesday, 07'th Apr 2020
BOSTON, April 07, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
Albireo Pharma (ALBO) Received its Third Buy in a Row
02:26pm, Friday, 27'th Mar 2020
After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from William Blair.
